Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Päivärinta M:

Search results

Items: 1 to 20 of 31

1.

Comparison of mid-age-onset and late-onset Huntington's disease in Finnish patients.

Sipilä JOT, Kauko T, Päivärinta M, Majamaa K.

J Neurol. 2017 Oct;264(10):2095-2100. doi: 10.1007/s00415-017-8600-2. Epub 2017 Aug 28.

PMID:
28849405
2.

Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study.

Hensman Moss DJ, Pardiñas AF, Langbehn D, Lo K, Leavitt BR, Roos R, Durr A, Mead S; TRACK-HD investigators; REGISTRY investigators, Holmans P, Jones L, Tabrizi SJ.

Lancet Neurol. 2017 Sep;16(9):701-711. doi: 10.1016/S1474-4422(17)30161-8. Epub 2017 Jun 20.

PMID:
28642124
3.

SNCA mutation p.Ala53Glu is derived from a common founder in the Finnish population.

Pasanen P, Palin E, Pohjolan-Pirhonen R, Pöyhönen M, Rinne JO, Päivärinta M, Martikainen MH, Kaasinen V, Hietala M, Gardberg M, Saukkonen AM, Eerola-Rautio J, Kaakkola S, Lyytinen J, Tienari PJ, Paetau A, Suomalainen A, Myllykangas L.

Neurobiol Aging. 2017 Feb;50:168.e5-168.e8. doi: 10.1016/j.neurobiolaging.2016.10.014. Epub 2016 Oct 19.

PMID:
27838048
4.

Clinical manifestations of intermediate allele carriers in Huntington disease.

Cubo E, Ramos-Arroyo MA, Martinez-Horta S, Martínez-Descalls A, Calvo S, Gil-Polo C; European HD Network.

Neurology. 2016 Aug 9;87(6):571-8. doi: 10.1212/WNL.0000000000002944. Epub 2016 Jul 8.

PMID:
27402890
5.

Low Occurrence of Extended-Spectrum β-lactamase-Producing Escherichia coli in Finnish Food-Producing Animals.

Päivärinta M, Pohjola L, Fredriksson-Ahomaa M, Heikinheimo A.

Zoonoses Public Health. 2016 Dec;63(8):624-631. doi: 10.1111/zph.12277. Epub 2016 May 24.

PMID:
27215423
6.

Clinical and imaging findings in Parkinson disease associated with the A53E SNCA mutation.

Martikainen MH, Päivärinta M, Hietala M, Kaasinen V.

Neurol Genet. 2015 Oct 15;1(4):e27. doi: 10.1212/NXG.0000000000000027. eCollection 2015 Dec.

7.

Why We Still Need More Research on the Epidemiology of Huntington's Disease.

Sipilä JO, Päivärinta M.

Neuroepidemiology. 2016;46(2):154-5. doi: 10.1159/000444230. Epub 2016 Feb 3. No abstract available.

8.

Akinetic crisis in Parkinson's disease is associated with a severe loss of striatal dopamine transporter function: a report of two cases.

Kaasinen V, Joutsa J, Noponen T, Päivärinta M.

Case Rep Neurol. 2014 Nov 26;6(3):275-80. doi: 10.1159/000369448. eCollection 2014 Sep.

9.

Epidemiology of Huntington's disease in Finland.

Sipilä JO, Hietala M, Siitonen A, Päivärinta M, Majamaa K.

Parkinsonism Relat Disord. 2015 Jan;21(1):46-9. doi: 10.1016/j.parkreldis.2014.10.025. Epub 2014 Nov 3.

PMID:
25466405
10.

Brain dopamine transporter binding and glucose metabolism in progressive supranuclear palsy-like creutzfeldt-jakob disease.

Rissanen E, Kaasinen V, Sonninen P, Röyttä M, Päivärinta M.

Case Rep Neurol. 2014 Jan 31;6(1):28-33. doi: 10.1159/000358483. eCollection 2014 Jan.

11.

The V471A polymorphism in autophagy-related gene ATG7 modifies age at onset specifically in Italian Huntington disease patients.

Metzger S, Walter C, Riess O, Roos RA, Nielsen JE, Craufurd D; REGISTRY Investigators of the European Huntington’s Disease Network, Nguyen HP.

PLoS One. 2013 Jul 22;8(7):e68951. doi: 10.1371/journal.pone.0068951. Print 2013.

12.

Suicidal ideation in a European Huntington's disease population.

Hubers AA, van Duijn E, Roos RA, Craufurd D, Rickards H, Bernhard Landwehrmeyer G, van der Mast RC, Giltay EJ; REGISTRY investigators of the European Huntington's Disease Network.

J Affect Disord. 2013 Oct;151(1):248-58. doi: 10.1016/j.jad.2013.06.001. Epub 2013 Jul 20.

13.

[Progressive multifocal leukoencephalopathy as a complication of natalizumab therapy].

Soilu-Hänninen M, Päivärinta M, Sonninen P, Parkkola R, Vuorinen T, Erälinna JP.

Duodecim. 2013;129(7):765-70. Finnish.

PMID:
23720945
14.

Normal dopamine transporter SPECT in neuropathologically confirmed corticobasal degeneration.

Kaasinen V, Gardberg M, Röyttä M, Seppänen M, Päivärinta M.

J Neurol. 2013 May;260(5):1410-1. doi: 10.1007/s00415-013-6886-2. Epub 2013 Mar 8. No abstract available.

PMID:
23471615
15.

Successful treatment of POLG-related mitochondrial epilepsy with antiepileptic drugs and low glycaemic index diet.

Martikainen MH, Päivärinta M, Jääskeläinen S, Majamaa K.

Epileptic Disord. 2012 Dec;14(4):438-41. doi: 10.1684/epd.2012.0543.

16.

CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion.

Lee JM, Ramos EM, Lee JH, Gillis T, Mysore JS, Hayden MR, Warby SC, Morrison P, Nance M, Ross CA, Margolis RL, Squitieri F, Orobello S, Di Donato S, Gomez-Tortosa E, Ayuso C, Suchowersky O, Trent RJ, McCusker E, Novelletto A, Frontali M, Jones R, Ashizawa T, Frank S, Saint-Hilaire MH, Hersch SM, Rosas HD, Lucente D, Harrison MB, Zanko A, Abramson RK, Marder K, Sequeiros J, Paulsen JS; PREDICT-HD study of the Huntington Study Group (HSG), Landwehrmeyer GB; REGISTRY study of the European Huntington's Disease Network, Myers RH; HD-MAPS Study Group, MacDonald ME, Gusella JF; COHORT study of the HSG.

Neurology. 2012 Mar 6;78(10):690-5. doi: 10.1212/WNL.0b013e318249f683. Epub 2012 Feb 8.

17.

Double trouble: spinal muscular atrophy type II and seropositive myasthenia gravis in the same patient.

Jokela M, Udd B, Päivärinta M.

Neuromuscul Disord. 2012 Feb;22(2):129-30. doi: 10.1016/j.nmd.2011.07.011. Epub 2011 Aug 20.

PMID:
21862330
18.

Discrepancies in reporting the CAG repeat lengths for Huntington's disease.

Quarrell OW, Handley O, O'Donovan K, Dumoulin C, Ramos-Arroyo M, Biunno I, Bauer P, Kline M, Landwehrmeyer GB; European Huntington’s Disease Network.

Eur J Hum Genet. 2012 Jan;20(1):20-6. doi: 10.1038/ejhg.2011.136. Epub 2011 Aug 3.

19.

Observing Huntington's disease: the European Huntington's Disease Network's REGISTRY.

Orth M; European Huntington's Disease Network, Handley OJ, Schwenke C, Dunnett S, Wild EJ, Tabrizi SJ, Landwehrmeyer GB.

J Neurol Neurosurg Psychiatry. 2011 Dec;82(12):1409-12. doi: 10.1136/jnnp.2010.209668. Epub 2010 Nov 19. No abstract available.

PMID:
21097549
20.

Normal and mutant HTT interact to affect clinical severity and progression in Huntington disease.

Aziz NA, Jurgens CK, Landwehrmeyer GB; EHDN Registry Study Group, van Roon-Mom WM, van Ommen GJ, Stijnen T, Roos RA.

Neurology. 2009 Oct 20;73(16):1280-5. doi: 10.1212/WNL.0b013e3181bd1121. Epub 2009 Sep 23. Erratum in: Neurology. 2009 Nov 10;73(19):1608. Neurology. 2011 Jan 11;76(2):202. Ciarmielo, Andrea [corrected to Ciarmiello, Andrea].

PMID:
19776381

Supplemental Content

Loading ...
Support Center